We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

New Glucose Biosensor Introduced for Diabetes Management

By LabMedica International staff writers
Posted on 11 Feb 2019
Print article
Image: The Saliva Glucose Biosensor that measures glucose in saliva rather than blood (Photo courtesy of iQ Group Global).
Image: The Saliva Glucose Biosensor that measures glucose in saliva rather than blood (Photo courtesy of iQ Group Global).
The world’s first saliva-based glucose test for diabetes management that measures glucose in saliva rather than blood has been introduced. The core scientific innovation of the biosensor lies in the patent protected modified organic thin film transistor architecture, incorporating Glucose Oxidase (GOX) as the recognition element to initiate an electrochemical reaction that produces an electrical signal.

This electrical signal can be displayed on the patient’s smart device in real time. The biosensor exhibits high sensitivity hence is able to detect glucose levels at considerably lower levels than in blood. It has a linear glucose sensing capability at concentrations of 100 times lower than current blood measuring methodologies.

The Saliva Glucose Biosensor (iQ Group Global, Sydney, Australia) is comprised of the Glucose Biosensor Unit and a digital healthcare app. The Glucose Biosensor Unit is a small, disposable strip, which when exposed to an individual’s saliva instantly provides a glucose measurement. The glucose measurement will be presented in real-time, via a proprietary digital app on a patient’s smart device.

The glucose measurement recorded by the biosensor will be presented via the proprietary digital app on the patient’s smart device in real-time where the patients may also compare historic glucose levels. This will open significant opportunities to improve the way diabetes is monitored and managed, enabling patients to store and analyze their data, share monitoring data with their healthcare team or relatives, create and send automated reminders when it is time to test glucose levels, offer educational services, and act as a provider for healthcare companies who offer patient support programs.

George Syrmalis, PhD, Chief Executive Officer and Chairman of the iQ Group Global, said, “Diabetes is a global epidemic, with 1 in 11 adults living with the disease. Achieving normoglycemia is one of the main targets for diabetes patients. However, finger prick testing is a painful and frustrating process, with many citing the pain as the main reason for poor adherence to testing protocols. By eradicating the need for finger prick blood tests, the saliva-based test will lead to increased glucose monitoring and better healthcare outcomes among these patients.”

Related Links:
iQ Group Global


Print article

Channels

Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more

Industry

view channel
Illustration

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.